These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18272039)

  • 1. Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
    Lu GY; Shen L; Wang ZY; Guo XF; Bai X; Su J; Ruan CG
    Chin Med J (Engl); 2008 Jan; 121(2):133-6. PubMed ID: 18272039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The association of von Willebrand factor and von Willebrand factor-cleaving protease in systemic lupus erythematosus].
    Lu GY; Guo XF; Wang ZY; Bai X; Su J; Ruan CG
    Zhonghua Nei Ke Za Zhi; 2006 Jan; 45(1):42-4. PubMed ID: 16624087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Residual collagen binding assay for von Willebrand factor-cleaving protease activity and its clinical application].
    Gao WQ; Su J; Xing XP; Wang JH; Bai X; Wang ZY; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):726-9. PubMed ID: 15631648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.
    Tan Y; Luan ZQ; Hao JB; Song D; Yu F; Zhao MH
    Lupus; 2018 Mar; 27(3):389-398. PubMed ID: 28786769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
    Molvarec A; Rigó J; Bõze T; Derzsy Z; Cervenak L; Makó V; Gombos T; Udvardy ML; Hársfalvi J; Prohászka Z
    Thromb Haemost; 2009 Feb; 101(2):305-11. PubMed ID: 19190814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of von Willebrand factor-cleaving protease activity in patients with thrombotic thrombocytopenic purpura.
    Gao WQ; Su J; Bai X; Wang ZY; Ruan CG
    Chin Med J (Engl); 2004 Jun; 117(6):818-22. PubMed ID: 15198879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.
    He S; Cao H; Magnusson CG; Eriksson-Berg M; Mehrkash M; Schenck-Gustafsson K; Blombäck M
    Thromb Res; 2001 Aug; 103(3):241-8. PubMed ID: 11672586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.
    Reiter RA; Varadi K; Turecek PL; Jilma B; Knöbl P
    Thromb Haemost; 2005 Mar; 93(3):554-8. PubMed ID: 15735809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
    Matsukawa M; Kaikita K; Soejima K; Fuchigami S; Nakamura Y; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Shimomura H; Sugiyama S; Fujimoto K; Yoshimura M; Nakagaki T; Ogawa H
    Am J Cardiol; 2007 Sep; 100(5):758-63. PubMed ID: 17719316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical application of a method for evaluating von Willebrand factor cleaving protease activity].
    Lin FQ; Li MF; Liu Q; Li ZY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1176-9. PubMed ID: 17715019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
    Freynhofer MK; Gruber SC; Bruno V; Höchtl T; Farhan S; Zaller V; Wojta J; Huber K
    Int J Cardiol; 2013 Sep; 168(1):317-25. PubMed ID: 23041092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.
    Miura M; Kaikita K; Matsukawa M; Soejima K; Fuchigami S; Miyazaki Y; Ono T; Uemura T; Tsujita K; Hokimoto S; Sumida H; Sugiyama S; Matsui K; Yamabe H; Ogawa H
    Thromb Haemost; 2010 Mar; 103(3):623-9. PubMed ID: 20135067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.
    Qu L; Jiang M; Qiu W; Lu S; Zhao Y; Xia L; Ruan C; Zhao Y
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):252-9. PubMed ID: 25916953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.
    Kokame K; Matsumoto M; Soejima K; Yagi H; Ishizashi H; Funato M; Tamai H; Konno M; Kamide K; Kawano Y; Miyata T; Fujimura Y
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11902-7. PubMed ID: 12181489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Measurement of plasma von Willebrand factor cleaving protease in patients with varied thrombotic microangiopathy].
    Katagiri H; Kawai Y; Sugizaki N; Sakai K; Handa M; Okamoto S; Watanabe K
    Rinsho Byori; 2003 Jun; 51(6):516-21. PubMed ID: 12884737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between reduced ADAMTS13 and diabetic nephropathy.
    Taniguchi S; Hashiguchi T; Ono T; Takenouchi K; Nakayama K; Kawano T; Kato K; Matsushita R; Nagatomo M; Nakamura S; Nakashima T; Maruyama I
    Thromb Res; 2010 Jun; 125(6):e310-6. PubMed ID: 20307901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina.
    Fuchigami S; Kaikita K; Soejima K; Matsukawa M; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Nakagaki T; Sugiyama S; Ogawa H
    Thromb Res; 2008; 122(5):618-23. PubMed ID: 18295305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation.
    Uemura T; Kaikita K; Yamabe H; Soejima K; Matsukawa M; Fuchigami S; Tanaka Y; Morihisa K; Enomoto K; Sumida H; Sugiyama S; Ogawa H
    Thromb Res; 2009 May; 124(1):28-32. PubMed ID: 18996572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies.
    Oleksowicz L; Bhagwati N; DeLeon-Fernandez M
    Cancer Res; 1999 May; 59(9):2244-50. PubMed ID: 10232615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome.
    Hugenholtz GC; Adelmeijer J; Meijers JC; Porte RJ; Stravitz RT; Lisman T
    Hepatology; 2013 Aug; 58(2):752-61. PubMed ID: 23468040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.